The External Quality Assurance Program Oversight Laboratory (EQAPOL) is a National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)-Division of AIDS (DAIDS) funded resource located at Duke Human Vaccine Institute's (DHVI) Immunology and Virology Quality Assessment Center (IVQAC); to support the development, implementation and oversight of external quality assurance programs that monitor laboratories involved in HIV/AIDS research and vaccine trials around the world.
The EQAPOL Program consists of the following components:
- Maintain a Peripheral Blood Mononuclear Cell (PBMC) Cell Bank and Reagent Repository
- An Enzyme-linked Immunosorbent Spot (ELISpot) Assay External Quality Assurance (EQA) Program
- An EQA Program for Flow Cytometry-based Assays
- Establish and Characterize Unique Clade-Specific HIV Virus Panels
- A Luminex EQA Program
- Validate an A3R5 Neutralization Assay and administer an EQA Program
- A Limiting Antigen (LAg) Avidity Incidence Assay EQA Program
- Create a Central Web Database for the Above Activities
The Duke Human Vaccine Institute has received a federal contract to manufacture a pan-coronavirus vaccine candidate that can be tested in a phase 1 clinical trial.
Awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the base period of the contract provides $11.2 million to support the program; additional provisions in the contract could increase the total funding up to $21.5 million if all option periods are exercised.
DURHAM, N.C. -- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.